EVMN

Evommune Inc

12.14

Jul 17 • 03:59PM ET +0.43 (3.67%)

12.13

Aftermarket • 07:44PM ET -0.01 (-0.08%)

Healthcare Biotechnology USA Small NYSE

Peers: KYMR NUVL RYTM INCY BMRN VKTX KRYS AXSM MDGL NBIX

| Held by: VTI IWM VXF FESM IWO VTWO SCHA IWC SBIO VHT

Index	RUT
Market Cap	437.26M
Enterprise Value	234.91M
Income	-75.99M
Sales	10.00M
Book/sh	8.46
Cash/sh	5.87
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	48
IPO	Nov 06, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	43.73
P/B	1.44
P/C	2.07
P/FCF	-
EV/EBITDA	-
EV/Sales	23.49
Quick Ratio	20.36
Current Ratio	20.36
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-2.39
EPS next Y	-3.21
EPS next Q	-0.66
EPS this Y	73.38%
EPS next Y	-7.40%
EPS next 5Y	33.72%
EPS past 3/5Y	-38.91% -
Sales past 3/5Y	61.25% -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-33.00%
Sales Q/Q	-100.00%
Earnings	May 07 AMC
EPS/Sales Surpr.	21.28% -100.00%

Insider Own	46.50%
Insider Trans	-0.53%
Inst Own	65.40%
Inst Trans	26.73%
ROA	-40.15%
ROE	-103.87%
ROIC	-24.37%
Gross Margin	86.39%
Oper. Margin	-899.92%
Profit Margin	-759.87%
SMA20	-24.41%
SMA50	-37.80%
SMA200	-43.01%
Trades

Shs Outstand	36.02M
Shs Float	19.27M
Short Float	24.80%
Short Ratio	6.47
Short Interest	4.78M
52W High	33.20 -63.43%
52W Low	11.55 5.11%
Volatility	7.60% 9.44%
ATR (14)	1.51
RSI (14)	32.72
Beta	-
Rel Volume	1.04
Avg Volume	738.40K
Volume	769,879

Perf Week	-8.10%
Perf Month	-39.45%
Perf Quarter	-54.65%
Perf Half Y	-42.87%
Perf YTD	-29.09%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.45
Target Price	32.89
Prev Close	11.71
Price	12.14
Change	3.67%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-30-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-29-26	Downgrade	William Blair	Outperform → Mkt Perform
May-01-26	Initiated	Stifel	Buy	$54
Apr-07-26	Resumed	Oppenheimer	Outperform	$50
Jan-22-26	Initiated	Oppenheimer	Outperform	$42
Jan-08-26	Initiated	Raymond James	Strong Buy	$40
Jan-06-26	Initiated	H.C. Wainwright	Buy	$35
Dec-01-25	Initiated	William Blair	Outperform
Dec-01-25	Initiated	Morgan Stanley	Overweight	$36
Dec-01-25	Initiated	Leerink Partners	Outperform	$42
Dec-01-25	Initiated	Evercore ISI	Outperform	$40
Dec-01-25	Initiated	Cantor Fitzgerald	Overweight

Show Previous Ratings

Jun-29-26 11:28AM	Evommune terminates oral drugs development in CSU (Clinical Trials Arena) -40.23%
10:16AM	Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN) (InvestorsHub)
08:30AM	Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria (Business Wire)
May-07-26 04:05PM	Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights (Business Wire) -5.58%
Apr-10-26 04:00AM	Biotechs IPO comeback; Trumps tariff loophole for pharma (Pharma Voice) -10.96%
04:00AM	Loading…
Apr-07-26 04:00AM	Evommune bucked biotech IPO drought and is focused on the long game (Pharma Voice)
Apr-06-26 09:00AM	Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine (Business Wire)
Mar-23-26 08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
Mar-18-26 01:16PM	Evommune Stock Sees RS Rating Rise To 91 (Investor's Business Daily)
09:34AM	Block upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
Mar-05-26 04:01PM	Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights (Business Wire) +6.36% +5.62%
Feb-25-26 10:27AM	Evommune CEO Luis Pena Reveals Whats Behind Companys Post-IPO Success (NYSE) +7.10%
Feb-15-26 09:59AM	Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Benzinga)
Feb-12-26 08:30PM	Evommune Announces $125 Million Private Placement (Business Wire) +13.24%
09:46AM	Evommune Stock Cools Off After Big Rally On Successful Eczema Trial (Benzinga)
07:53AM	Loading…
Feb-11-26 07:53AM	Evommunes stock rallies 70% on Phase IIa eczema data (Clinical Trials Arena)
04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily) +70.87%
12:29PM	Evommune's Stock Surges On Strong Results For New Eczema Drug (Benzinga)
09:12AM	Evommune Nearly Doubles - Has Dupixent Met Its Match In Eczema? (Investor's Business Daily)
07:30AM	Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis (Business Wire)
Jan-19-26 11:28AM	High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 (MarketBeat)
Dec-11-25 04:05PM	Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire) -8.53%
Dec-01-25 09:46AM	Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls (The Fly)
Nov-06-25 03:39PM	What Shutdown? The IPO Window Is Still Open for Some Companies (Barrons.com)
08:55AM	NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading (PR Newswire)
Nov-05-25 07:45PM	Evommune Announces Pricing of its Initial Public Offering (PR Newswire)

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

FounderMr. Luis C. Pena

M.B.A.Mr. Kyle Carver CPA

Chief Business & Legal OfficerMr. Gregory S. Moss Esq.

Co-FounderDr. Eugene Andrew Bauer M.D.

Chief Scientific OfficerDr. Jeegar Patel Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carver Kyle	Chief Financial Officer	Jul 08 '26	Buy	13.26	1,000	13,260	60,335	Jul 10 07:59 PM
KIRSCH ARTHUR S	Director	Jul 07 '26	Buy	13.30	10,000	133,000	10,000	Jul 08 08:00 PM
Drew Janice Suzann	Chief of Dev. Operations	Jun 22 '26	Option Exercise	3.15	20,000	63,063	87,794	Jun 24 08:00 PM
Drew Janice Suzann	Chief of Dev. Operations	Jun 22 '26	Sale	22.63	20,000	452,600	67,794	Jun 24 08:00 PM
Patel Jeegar Pravinkumar	Chief Scientific Officer	Jun 22 '26	Option Exercise	3.84	1,488	5,714	47,891	Jun 24 08:00 PM
Patel Jeegar Pravinkumar	Chief Scientific Officer	Jun 22 '26	Sale	22.50	1,488	33,480	46,403	Jun 24 08:00 PM
Pena Luis C.	President & CEO	Jun 22 '26	Sale	22.71	7,438	168,917	630,458	Jun 24 07:59 PM
JANICE DREW	Officer	Jun 22 '26	Proposed Sale	21.36	20,000	427,200		Jun 22 04:45 PM
Cohen David E	Director	Jun 02 '26	Sale	20.33	6,056	123,094	17,609	Jun 03 08:03 PM
Patel Jeegar Pravinkumar	Chief Scientific Officer	Jun 01 '26	Option Exercise	3.84	13,512	51,886	63,090	Jun 03 08:02 PM
Patel Jeegar Pravinkumar	Chief Scientific Officer	Jun 01 '26	Sale	22.74	16,687	379,462	46,403	Jun 03 08:02 PM
Pena Luis C.	President & CEO	Jun 01 '26	Sale	22.74	16,787	381,736	637,896	Jun 03 08:02 PM
DAVID COHEN	Director	Jun 02 '26	Proposed Sale	22.17	9,258	205,250		Jun 02 04:37 PM
Moss Gregory S.	Chief Business & Legal Officer	May 28 '26	Option Exercise	1.71	14,223	24,321	75,058	Jun 01 08:00 PM
Moss Gregory S.	Chief Business & Legal Officer	May 28 '26	Sale	22.83	14,223	324,711	60,835	Jun 01 08:00 PM
Carver Kyle	Chief Financial Officer	May 28 '26	Option Exercise	2.99	15,000	44,850	77,510	Jun 01 07:59 PM
Carver Kyle	Chief Financial Officer	May 28 '26	Sale	22.84	18,175	415,117	59,335	Jun 01 07:59 PM
LUIS PENA	Director	Jun 01 '26	Proposed Sale	23.23	24,225	562,747		Jun 01 04:46 PM
JEEGAR PATEL	Officer	Jun 01 '26	Proposed Sale	23.23	18,175	422,205		Jun 01 04:46 PM
GREGORY MOSS	Officer	May 28 '26	Proposed Sale	23.34	14,223	331,965		May 28 04:35 PM
KYLE CARVER	Officer	May 28 '26	Proposed Sale	23.34	25,675	599,254		May 28 04:35 PM
Hopfner Robert Lorne	Director	Dec 19 '25	Buy	17.35	1,000	17,350	4,026	Dec 22 07:07 AM

Open in Screener

LQDA

Liquidia Corp

79.94

Jul 17 • 03:59PM ET +4.67 (6.20%)

79.51

Aftermarket • 06:15PM ET -0.43 (-0.54%)

Healthcare Drug Manufacturers - Specialty & Generic USA Mid NASD

Peers: AMRX BHC ALKS INDV LNTH KNSA VTRS TEVA BMRN TLX

| Held by: IJR VTI IWM VXF IJT IWO SPSM VTWO SLYG SCHA

Index	RUT
Market Cap	7.11B
Enterprise Value	7.07B
Income	22.30M
Sales	288.06M
Book/sh	1.23
Cash/sh	2.51
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	216
IPO	Jul 26, 2018

P/E	564.55
Forward P/E	14.03
PEG	-
P/S	24.68
P/B	65.02
P/C	31.91
P/FCF	172.76
EV/EBITDA	150.03
EV/Sales	24.55
Quick Ratio	2.03
Current Ratio	2.22
Debt/Eq	1.70
LT Debt/Eq	1.23
Option/Short	Yes / Yes

EPS (ttm)	0.14
EPS next Y	5.70
EPS next Q	0.76
EPS this Y	514.50%
EPS next Y	71.77%
EPS next 5Y	-
EPS past 3/5Y	-5.98% 14.60%
Sales past 3/5Y	114.98% 192.49%
EPS Y/Y TTM	115.40%
Sales Y/Y TTM	1936.66%
EPS Q/Q	216.05%
Sales Q/Q	4158.49%
Earnings	May 11 BMO
EPS/Sales Surpr.	26.77% 11.24%

Insider Own	16.53%
Insider Trans	-16.78%
Inst Own	67.39%
Inst Trans	3.87%
ROA	7.09%
ROE	28.18%
ROIC	9.20%
Gross Margin	91.51%
Oper. Margin	15.81%
Profit Margin	7.74%
SMA20	3.53%
SMA50	19.65%
SMA200	91.03%
Trades

Shs Outstand	88.31M
Shs Float	73.74M
Short Float	17.87%
Short Ratio	6.92
Short Interest	13.18M
52W High	82.96 -3.64%
52W Low	14.04 469.37%
Volatility	8.37% 6.11%
ATR (14)	4.73
RSI (14)	59.32
Beta	0.59
Rel Volume	0.63
Avg Volume	1.90M
Volume	1,202,844

Perf Week	2.58%
Perf Month	17.54%
Perf Quarter	93.09%
Perf Half Y	99.90%
Perf YTD	131.78%
Perf Year	447.53%
Perf 3Y	934.15%
Perf 5Y	3110.44%
Perf 10Y	-
Recom	1.25
Target Price	74.25
Prev Close	75.27
Price	79.94
Change	6.20%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-29-26	Downgrade	BofA Securities	Buy → Neutral	$79
Oct-20-25	Initiated	Wells Fargo	Overweight	$31
Aug-15-25	Resumed	Jefferies	Buy	$43
May-19-25	Downgrade	Oppenheimer	Perform → Underperform	$13
Dec-20-24	Initiated	Wells Fargo	Overweight	$20
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform	$27
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy	$18 → $28
Sep-19-22	Resumed	Wedbush	Underperform	$3
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform	$3
Jul-22-22	Initiated	Ladenburg Thalmann	Buy	$15
May-31-22	Initiated	BTIG Research	Buy	$14
May-26-22	Initiated	BofA Securities	Buy	$12
Dec-04-20	Initiated	H.C. Wainwright	Buy	$6
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral	$20 → $4
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform	$26
Aug-20-18	Initiated	Needham	Buy	$30

Show Previous Ratings

Jun-29-26 12:01PM	BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns (Investing.com)
Jun-11-26 08:30AM	Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions (GlobeNewswire) +9.77%
Jun-08-26 08:30AM	Liquidia Corporation Announces Inclusion in the S&P SmallCap 600 Index (GlobeNewswire)
Jun-05-26 07:25PM	Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
May-27-26 08:30AM	Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
03:03AM	Loading…
May-12-26 03:03AM	Liquidia Corp (LQDA) Q1 2026 Earnings Call Highlights: Record Growth and Strategic Expansion (GuruFocus.com) +6.53%
May-11-26 04:56PM	Liquidia Corporation Q1 2026 Earnings Call Summary (Moby) +25.60%
10:10AM	Liquidia (LQDA) Shares Rise After Strong Q1 Earnings and Revenue Beat (InvestorsHub)
06:30AM	Liquidia Corporation Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-06-26 08:30AM	Liquidia Corporation to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.01%
May-04-26 08:30AM	Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026 (GlobeNewswire)
Apr-07-26 08:00AM	Liquidia Corporation to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-03-26 08:00PM	Does Liquidia Corporation (LQDA) Have the Potential to Rally 34.47% as Wall Street Analysts Expect? (Quartz)
Mar-10-26 10:00AM	Best Momentum Stocks to Buy for March 10th (Zacks) +8.25%
Mar-05-26 10:10PM	Liquidia Q4 Earnings Call Highlights (MarketBeat)
04:02PM	Loading…
04:02PM	Liquidia Corp (LQDA) Q4 2025 Earnings Call Highlights: Record Sales Surge and Strategic Growth (GuruFocus.com)
08:30AM	Liquidia Corporation Q4 2025 Earnings Call Summary (Moby)
07:45AM	Liquidia Corporation (LQDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-26 12:15PM	Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026 (GlobeNewswire)
Feb-16-26 11:07AM	Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling (Insider Monkey)
Feb-12-26 11:40AM	EXEL or LQDA: Which Is the Better Value Stock Right Now? (Zacks)
Jan-27-26 08:30AM	Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress (GlobeNewswire)
Jan-16-26 08:29AM	Laughing Water Capital's Updates on Liquidia Corp (LQDA) (Insider Monkey)
Jan-15-26 12:00PM	Liquidia Corporation (LQDA) is a Great Momentum Stock: Should You Buy? (Zacks)
Jan-09-26 07:09PM	Why Liquidia Stock Rocked the Market Today (Motley Fool) +12.91%
06:30AM	Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update (GlobeNewswire)
Jan-08-26 11:40AM	HRMY vs. LQDA: Which Stock Is the Better Value Option? (Zacks)
Jan-07-26 07:00AM	Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
09:06AM	Loading…
Dec-15-25 09:06AM	Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus (Zacks)
Dec-11-25 09:22AM	Arquitos Capital Management's Updates on Liquidia Corporation (LQDA) (Insider Monkey)
Nov-24-25 09:55AM	Wall Street Analysts See a 51.15% Upside in Liquidia Corporation (LQDA): Can the Stock Really Move This High? (Zacks)
Nov-21-25 12:04PM	United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base (Investor's Business Daily)
Nov-16-25 10:14PM	Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA's 75% Growth in U.S. Prostacyclin Revenue (Insider Monkey)
Nov-06-25 09:55AM	Wall Street Analysts Think Liquidia Corporation (LQDA) Could Surge 62.34%: Read This Before Placing a Bet (Zacks)
Nov-05-25 06:39AM	Liquidia (LQDA) Climbs 10.7%, Nears 52-Week High on Strong Demand for Heart Treatment (Insider Monkey) -5.34%
Nov-03-25 04:02PM	Liquidia Corp (LQDA) Q3 2025 Earnings Call Highlights: Strong YUTREPIA Sales Drive Positive ... (GuruFocus.com) +10.67%
08:00AM	Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences (GlobeNewswire)
06:30AM	Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-25 09:21AM	Liquidia Corp (LQDA) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
Oct-28-25 10:00AM	Niagen Bioscience (NAGE) Reports Next Week: What to Expect (Zacks)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-27-25 08:30AM	Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-21-25 09:55AM	Wall Street Analysts Believe LIQUIDIA CORP (LQDA) Could Rally 50.94%: Here's is How to Trade (Zacks)
Oct-16-25 04:33PM	BofA Securities Raises Liquidia Corporation (LQDA) PT to $37, Reiterates Buy Rating (Insider Monkey)
Oct-07-25 06:30AM	Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 (GlobeNewswire) +5.10%
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
Sep-29-25 08:30AM	Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting (GlobeNewswire)
Sep-24-25 04:06AM	Liquidia Corporation (LQDA) Presents Strategic Overview at Well Fargo's Annual Healthcare Conference 2025 (Insider Monkey)
Sep-23-25 10:32AM	Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares? (Insider Monkey)
Sep-16-25 02:15PM	Liquidia Corporation (LQDA): A Bull Case Theory (Insider Monkey)
Sep-11-25 08:30AM	Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium (GlobeNewswire)
Sep-04-25 01:14PM	Jefferies Highlights Yutrepia's Market Edge in Supporting a Buy on Liquidia (LQDA) (Insider Monkey)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
Sep-01-25 01:04AM	BTIG Raises Price Target for Liquidia (LQDA), Keeps Buy Rating (Insider Monkey)
Aug-27-25 08:30AM	Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-18-25 11:40PM	Court Victory and Fresh Funding Propel Growth at Liquidia Corporation (Insider Monkey) +6.82%
Aug-13-25 12:54PM	Liquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge (Insider Monkey)
03:08AM	Liquidia Corp (LQDA) Q2 2025 Earnings Call Highlights: Strong YUTREPIA Launch and Financial Position (GuruFocus.com)
Aug-12-25 04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily) +13.68%
03:00PM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
06:30AM	Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:22AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q2 2025 Result (GuruFocus.com)
Aug-05-25 08:30AM	Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-31-25 09:15AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-24-25 08:00AM	Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? (Investor's Business Daily) +5.75%
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
08:59AM	Liquidia Receives $50M from HCRx, Accelerates YUTREPIA's Commercial Launch Following Favorable Court Ruling (Insider Monkey)
Jun-23-25 04:34PM	Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA (GlobeNewswire)
Jun-11-25 11:04AM	Insmed Stock Jumps 29% on Encouraging PAH Study Results (Zacks) -5.67%
Jun-10-25 04:07PM	Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia (Investor's Business Daily) -16.87%
Jun-02-25 06:30AM	Liquidia Schedules First Commercial Shipment of YUTREPIA (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD (GlobeNewswire) +13.07%
May-28-25 08:00AM	Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) -9.13%
May-24-25 10:47AM	FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute (Insider Monkey)
May-23-25 02:28PM	U.S. FDA Approves Liquidia's YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (GlobeNewswire)
May-12-25 06:00AM	Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics (GlobeNewswire)
May-09-25 03:21AM	Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... (GuruFocus.com)
May-08-25 11:06AM	Buckley Capital's Views on Liquidia Corp. (LQDA) (Insider Monkey)
07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 06:35PM	Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
11:16AM	Liquidia Q1 2025 Earnings Preview (Seeking Alpha)
10:15AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q1 2025 Result (GuruFocus.com)
May-06-25 08:00AM	Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference (GlobeNewswire)
May-05-25 04:06PM	Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month (Seeking Alpha)
09:50AM	Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains? (Zacks)
May-02-25 05:28PM	District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia (GlobeNewswire) +13.23%
May-01-25 08:00AM	Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-30-25 09:30AM	Arquitos Capital's Largest Holdings For Q1 2025 (Seeking Alpha)
Apr-29-25 07:40AM	Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates (Zacks) -5.06%
05:16AM	Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? (Zacks)
Apr-25-25 06:30AM	Arquitos Capital Management Q1 2025 Investor Letter (Seeking Alpha)
Apr-07-25 06:38AM	Liquidia: United Therapeutics Has The Last Laugh (Seeking Alpha)

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

CEO & DirectorDr. Roger A. Jeffs Ph.D.

COO & CFOMr. Michael Kaseta

General Counsel & Corporate SecretaryMr. Russell Schundler

Chief Commercial OfficerMr. Scott Moomaw

Chief Medical OfficerDr. Rajeev Saggar M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krepp Sarah	Chief Human Resource Officer	Jul 13 '26	Sale	71.51	7,864	562,361	117,178	Jul 14 08:11 PM
Khindri Sanjeev	Chief Development Officer	Jul 13 '26	Sale	71.51	1,185	84,740	65,947	Jul 14 08:09 PM
Kaseta Michael	CFO and COO	Jul 13 '26	Sale	71.51	20,430	1,460,965	345,805	Jul 14 08:08 PM
JEFFS ROGER	Chief Executive Officer	Jul 13 '26	Sale	71.51	35,249	2,520,683	1,130,426	Jul 14 08:07 PM
Adair Jason	Chief Business Officer	Jul 13 '26	Sale	71.51	7,863	562,289	217,126	Jul 14 08:05 PM
Schundler Russell	General Counsel	Jul 13 '26	Sale	71.51	14,738	1,053,926	605,962	Jul 14 08:04 PM
Saggar Rajeev	Chief Medical Officer	Jul 13 '26	Sale	71.51	9,926	709,816	171,799	Jul 14 08:02 PM
Moomaw Scott	Chief Commercial Officer	Jul 13 '26	Sale	71.51	9,539	682,142	182,485	Jul 14 08:01 PM
Boyle Dana	Chief Accounting Officer	Jul 13 '26	Sale	71.51	9,002	643,740	169,519	Jul 14 07:59 PM
Bloch Stephen M	Director	Jul 07 '26	Sale	80.94	50,000	4,046,795	780,073	Jul 08 04:30 PM
Bloch Stephen M	Director	Jul 06 '26	Sale	80.17	25,000	2,004,375	830,073	Jul 08 04:30 PM
Bloch Stephen M	Director	Jul 01 '26	Sale	79.47	25,000	1,986,695	855,073	Jul 06 05:44 PM
Bloch Stephen M	Director	Jun 22 '26	Sale	75.74	100,000	7,573,704	880,073	Jun 24 04:30 PM
Bloch Stephen M	Director	Jun 12 '26	Sale	71.46	111,049	7,936,094	1,065,135	Jun 16 04:30 PM
Bloch Stephen M	Director	Jun 15 '26	Sale	71.44	85,062	6,076,486	980,073	Jun 16 04:30 PM
Krepp Sarah	Chief Human Resource Officer	Jun 11 '26	Sale	70.28	24,880	1,748,527	121,863	Jun 15 04:30 PM
Bloch Stephen M	Director	Jun 11 '26	Sale	70.43	242,269	17,062,444	1,176,184	Jun 12 04:30 PM
Bloch Stephen M	Director	Jun 10 '26	Sale	65.58	145,954	9,572,345	1,418,453	Jun 12 04:30 PM
SARAH KREPP	Officer	Jun 11 '26	Proposed Sale	65.25	24,880	1,623,420		Jun 11 04:26 PM
Canaan VIII LP	Director	Jun 10 '26	Proposed Sale	65.00	200,000	13,000,000		Jun 10 04:52 PM
Khindri Sanjeev	Chief Development Officer	Jun 08 '26	Sale	65.46	4,134	270,612	67,132	Jun 10 04:31 PM
Bloch Stephen M	Director	Jun 08 '26	Sale	64.76	148,301	9,603,989	1,636,941	Jun 10 04:30 PM
Bloch Stephen M	Director	Jun 09 '26	Sale	64.38	72,534	4,669,693	1,564,407	Jun 10 04:30 PM
Manning Paul B	Director	Jun 04 '26	Sale	63.91	200,000	12,782,059	716,311	Jun 08 04:41 PM
Bloch Stephen M	Director	Jun 04 '26	Sale	64.97	82,736	5,375,398	1,787,306	Jun 08 04:30 PM
Bloch Stephen M	Director	Jun 05 '26	Sale	64.14	2,064	132,384	1,785,242	Jun 08 04:30 PM
Canaan VIII LP	Director	Jun 08 '26	Proposed Sale	64.00	200,000	12,800,000		Jun 08 04:11 PM
Paul B Manning	Director	Jun 04 '26	Proposed Sale	55.69	200,000	11,138,000		Jun 04 06:38 PM
Canaan VIII LP	Director	Jun 04 '26	Proposed Sale	65.00	200,000	13,000,000		Jun 04 05:24 PM
Krepp Sarah	Chief Human Resource Officer	Jun 01 '26	Sale	60.87	276	16,800	146,743	Jun 03 04:31 PM
KIRSCH ARTHUR S	Director	Jun 01 '26	Sale	60.22	15,000	903,300	15,000	Jun 03 04:30 PM
KIRSCH ARTHUR S	Director	Jun 03 '26	Sale	54.80	10,000	548,000	0	Jun 03 04:30 PM
KIRSCH ARTHUR S	Director	Jun 02 '26	Sale	56.00	5,000	280,000	10,000	Jun 03 04:30 PM
KIRSCH ARTHUR S	Director	Jun 01 '26	Proposed Sale	61.37	30,000	1,841,100		Jun 01 09:56 AM
JEFFS ROGER	Chief Executive Officer	May 27 '26	Sale	62.18	6,428	399,712	1,041,667	May 28 04:30 PM
SINGH RAMAN	Director	May 21 '26	Option Exercise	9.44	29,494	278,352	68,249	May 26 06:17 PM
SINGH RAMAN	Director	May 21 '26	Sale	60.13	29,494	1,773,436	38,755	May 26 06:17 PM
JEFFS ROGER	Chief Executive Officer	May 22 '26	Sale	61.52	25,000	1,538,055	1,073,095	May 26 06:16 PM
JEFFS ROGER	Chief Executive Officer	May 21 '26	Sale	61.13	25,000	1,528,160	1,098,095	May 26 06:16 PM
JEFFS ROGER	Chief Executive Officer	May 26 '26	Sale	60.38	25,000	1,509,460	1,048,095	May 26 06:16 PM
RAMANDEEP SINGH	Director	May 21 '26	Proposed Sale	60.13	29,494	1,773,437		May 21 05:12 PM
Caligan Partners LP	Director	May 19 '26	Buy	59.98	5,300	317,894	8,138,951	May 20 08:51 PM
Caligan Partners LP	Director	May 19 '26	Sale	59.98	5,300	317,894	8,133,651	May 20 08:51 PM
JEFFS ROGER	Chief Executive Officer	May 20 '26	Sale	61.30	25,000	1,532,548	1,123,095	May 20 06:55 PM
JEFFS ROGER	Chief Executive Officer	May 19 '26	Sale	58.65	25,000	1,466,142	1,148,095	May 20 06:55 PM
JEFFS ROGER	Chief Executive Officer	May 18 '26	Sale	56.77	25,000	1,419,320	1,173,095	May 20 06:55 PM
SERENDIPITY BIOPHARMA LLC	Director	May 20 '26	Proposed Sale	59.98	106,428	6,383,551		May 20 04:37 PM
JEFFS ROGER	Chief Executive Officer	May 14 '26	Sale	58.62	25,000	1,465,565	1,223,095	May 15 06:59 PM
JEFFS ROGER	Chief Executive Officer	May 15 '26	Sale	57.04	25,000	1,426,072	1,198,095	May 15 06:59 PM
JEFFS ROGER	Chief Executive Officer	May 13 '26	Sale	56.29	25,000	1,407,128	1,248,095	May 15 06:59 PM
SERENDIPITY BIOPHARMA LLC	Director	May 14 '26	Proposed Sale	57.59	100,000	5,759,000		May 14 04:26 PM
Bloch Stephen M	Director	May 11 '26	Sale	50.23	318,893	16,016,775	1,870,042	May 13 04:30 PM
JEFFS ROGER	Chief Executive Officer	May 12 '26	Sale	54.04	25,000	1,350,990	1,273,095	May 12 06:52 PM
JEFFS ROGER	Chief Executive Officer	May 08 '26	Sale	42.14	25,000	1,053,565	1,323,095	May 12 06:52 PM
JEFFS ROGER	Chief Executive Officer	May 11 '26	Sale	41.50	25,000	1,037,402	1,298,095	May 12 06:52 PM
Canaan VIII LP	Director	May 11 '26	Proposed Sale	49.86	318,893	15,900,000		May 11 05:52 PM
SERENDIPITY BIOPHARMA LLC	Director	May 08 '26	Proposed Sale	42.28	100,000	4,228,000		May 08 04:19 PM
JEFFS ROGER	Chief Executive Officer	May 07 '26	Sale	42.09	25,000	1,052,135	1,348,095	May 07 06:19 PM
JEFFS ROGER	Chief Executive Officer	May 06 '26	Sale	40.78	25,000	1,019,572	1,373,095	May 07 06:19 PM
JEFFS ROGER	Chief Executive Officer	May 05 '26	Sale	40.10	25,000	1,002,593	1,398,095	May 07 06:19 PM
SERENDIPITY BIOPHARMA LLC	Director	May 07 '26	Proposed Sale	42.14	25,000	1,053,500		May 07 04:18 PM
Boyle Dana	Chief Accounting Officer	Apr 27 '26	Sale	37.78	1,576	59,541	175,342	Apr 29 04:31 PM
Adair Jason	Chief Business Officer	Apr 27 '26	Sale	41.65	688	28,655	214,738	Apr 29 04:30 PM
JEFFS ROGER	Chief Executive Officer	Apr 17 '26	Sale	40.60	18,839	764,956	1,423,095	Apr 21 04:30 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 17 '26	Proposed Sale	41.40	68,839	2,849,935		Apr 17 04:39 PM
JEFFS ROGER	Chief Executive Officer	Apr 16 '26	Sale	40.31	25,000	1,007,800	1,441,934	Apr 16 08:38 PM
JEFFS ROGER	Chief Executive Officer	Apr 15 '26	Sale	40.14	25,000	1,003,522	1,466,934	Apr 16 08:38 PM
JEFFS ROGER	Chief Executive Officer	Apr 14 '26	Sale	40.00	3,300	132,000	1,491,934	Apr 16 08:38 PM
Kaseta Michael	CFO and COO	Apr 15 '26	Option Exercise	2.79	86,971	242,649	483,702	Apr 16 08:37 PM
Kaseta Michael	CFO and COO	Apr 14 '26	Option Exercise	2.79	3,000	8,370	408,775	Apr 16 08:37 PM
Kaseta Michael	CFO and COO	Apr 15 '26	Sale	40.14	139,390	5,595,240	353,356	Apr 16 08:37 PM
Kaseta Michael	CFO and COO	Apr 14 '26	Sale	40.00	3,000	120,000	405,775	Apr 16 08:37 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 16 '26	Proposed Sale	40.12	25,000	1,003,000		Apr 16 04:13 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 15 '26	Proposed Sale	38.71	24,733	957,414		Apr 15 04:43 PM
MICHAEL KASETA	Officer	Apr 15 '26	Proposed Sale	38.71	139,390	5,395,787		Apr 15 04:42 PM
Moomaw Scott	Chief Commercial Officer	Apr 13 '26	Sale	38.34	10,547	404,402	184,558	Apr 14 05:08 PM
Adair Jason	Chief Business Officer	Apr 13 '26	Sale	38.37	7,301	280,139	215,426	Apr 14 05:07 PM
Boyle Dana	Chief Accounting Officer	Apr 13 '26	Sale	38.37	5,101	195,725	176,918	Apr 14 05:07 PM
Kaseta Michael	CFO and COO	Apr 10 '26	Option Exercise	2.79	23,821	66,461	435,676	Apr 14 05:07 PM
Kaseta Michael	CFO and COO	Apr 10 '26	Sale	40.14	23,821	956,249	411,855	Apr 14 05:07 PM
Kaseta Michael	CFO and COO	Apr 13 '26	Sale	38.37	18,958	727,418	405,775	Apr 14 05:07 PM
Krepp Sarah	Chief Human Resource Officer	Apr 13 '26	Sale	38.37	4,557	174,852	147,019	Apr 14 05:06 PM
Saggar Rajeev	Chief Medical Officer	Apr 13 '26	Sale	38.37	9,220	353,771	173,270	Apr 14 05:06 PM
Schundler Russell	General Counsel	Apr 13 '26	Sale	38.37	13,692	525,362	610,532	Apr 14 05:05 PM
JEFFS ROGER	Chief Executive Officer	Apr 13 '26	Sale	38.37	32,744	1,256,387	1,137,599	Apr 14 05:05 PM
JEFFS ROGER	Chief Executive Officer	Apr 10 '26	Sale	40.12	21,433	859,877	1,495,234	Apr 14 05:05 PM
MICHAEL KASETA	Officer	Apr 14 '26	Proposed Sale	38.85	3,000	116,550		Apr 14 04:37 PM
JEFFS ROGER	Chief Executive Officer	Apr 09 '26	Sale	40.12	25,000	1,002,887	1,516,667	Apr 13 05:47 PM
Kaseta Michael	CFO and COO	Apr 09 '26	Option Exercise	2.80	133,789	374,032	545,644	Apr 13 05:47 PM
Kaseta Michael	CFO and COO	Apr 09 '26	Sale	40.24	133,789	5,383,388	411,855	Apr 13 05:47 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 10 '26	Proposed Sale	40.32	25,000	1,008,000		Apr 10 04:35 PM
MICHAEL KASETA	Officer	Apr 10 '26	Proposed Sale	40.32	23,821	960,463		Apr 10 04:34 PM
SERENDIPITY BIOPHARMA LLC	Director	Apr 09 '26	Proposed Sale	38.19	25,000	954,750		Apr 09 04:22 PM
MICHAEL KASETA	Officer	Apr 09 '26	Proposed Sale	38.19	133,789	5,109,402		Apr 09 04:21 PM
Bloch Stephen M	Director	Mar 27 '26	Sale	35.94	62,550	2,247,780	2,188,935	Mar 30 05:43 PM
Bloch Stephen M	Director	Mar 26 '26	Sale	37.22	7,684	285,985	2,251,485	Mar 30 05:43 PM
Canaan VIII LP	Board Member	Mar 27 '26	Proposed Sale	33.57	62,550	2,100,000		Mar 27 04:27 PM
Canaan VIII LP	Board Member	Mar 26 '26	Proposed Sale	37.09	7,684	285,000		Mar 26 04:21 PM
Moomaw Scott	Chief Commercial Officer	Mar 23 '26	Option Exercise	3.40	17,000	57,800	204,640	Mar 25 04:30 PM
Moomaw Scott	Chief Commercial Officer	Mar 23 '26	Sale	36.79	18,314	673,752	187,640	Mar 25 04:30 PM

EVMN

Evommune Inc

LQDA

Liquidia Corp

Upgrade your Finviz experience